About: High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design
Creator	Vaheri, Antti Lindholm, Dan Ghaemmaghami, Amir Avarlaid, Annela Baćević, Miljana Haring, Liina Jaago, Mariliis Kalso, Eija Lambert, France Palm, Kaia Pihlak, Arno Planken, Anu Planken, Margus Pupina, Nadežda Pussinen, Pirkko Rähni, Annika Sadam, Helle Tienari, Pentti Timmusk, Tõnis Vasar, Eero
Source	MedRxiv
abstract	Little is known about the quality of polyclonal antibody responses in COVID-19 patients, and how it correlates with disease severity or patients' prior exposure to other pathogens. The whole polyclonal antibody repertoire in a retrospective cohort of 538 individuals was mapped against SARS-CoV-2 spike (S) glycoprotein, the main target of antibody immune responses in SARS-CoV-2 infection. Bioinformatic predictions identified 15 major B cell epitopes for S of SARS-CoV-2. Several epitopes localised in RBD of S including those spanning the ACE2-binding site, the highly conserved cryptic epitope of the neutralizing antibody of SARS-CoV, and fusion/entry domains of HR1 and HR2 of S protein of SARS-CoV-2. Intriguingly, some of these epitopes have cross-reactivity to antigens of common pathogens, potentially affecting SARS-CoV-2 infection outcome. High level of anti-Spike SARS-CoV-2 seroreactivity in populations with no history of exposure to SARS-CoV-2 is of clinical relevance and could underpin better understanding of COVID-19 pathophysiology in different populations and provide a blueprint for design of effective vaccines and developing better strategies for antibody testing.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1101/2020.05.18.20105189
has license	medrxiv
sha1sum (hex)	33fb40de69545162c559ada7cf0191b7433ebe75
schema:url	https://doi.org/10.1101/2020.05.18.20105189
resource representing a document's title	High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design
resource representing a document's body	covid:33fb40de69545162c559ada7cf0191b7433ebe75#body_text
is schema:about of	named entity 'conserved' named entity 'infection' named entity 'neutralizing antibody' named entity 'antibody' named entity 'IDENTIFIED' named entity 'NO HISTORY OF' named entity 'LITTLE' named entity 'HR2' named entity 'SITE' named entity 'immune responses' named entity 'SARS-CoV-2' named entity 'HR2' named entity 'High' named entity 'epitopes' named entity 'amino acids' named entity 'glycoprotein' named entity 'SARS-CoV-2' named entity 'mapped' named entity 'blueprint' named entity 'B cell' named entity 'HR1' named entity 'polyclonal antibody' named entity 'patients' named entity 'The' named entity 'HR1' named entity 'SARS-CoV-2' named entity 'epitope' named entity 'epitopes' named entity 'highly conserved' named entity 'SARS-CoV-2' named entity 'polyclonal antibody' named entity 'retrospective cohort' named entity 'Bioinformatic' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'severe pneumonia' named entity 'pathogens' named entity 'protein motif' named entity 'SARS-CoV-2' named entity 'p-value' named entity 'clinical outcome' named entity 'epitopes' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'coronaviruses' named entity 'inflammation' named entity 'immune response' named entity 'immune responses' named entity 'structurally related' named entity 'receptor binding domain' named entity 'mimotope' named entity 'probability' named entity 'Sequence alignment' named entity 'type 2 diabetes' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'p<0.05' named entity 'peptide' named entity 'Ep7' named entity 'antibody response' named entity 'glycoprotein' named entity 'antigens' named entity 'COVID' named entity 'CAD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software